Clinical Trials
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded Phase 2...
News
I Holland Present their Latest Tablet Tooling Developments to a Virtual Audience at ACHEMA Pulse
I Holland, the world’s best-known manufacturer of tablet punches and dies for the pharmaceutical and nutraceutical industries, has announced it will be exhibiting some of it most innovative products at ACHEMA Pulse from 15-19 June, including the new die...
News
Vaccine Passports in NHS app unethical if they don’t allow date custodianship say FarmaTrust
FarmaTrust, the UK-based global medical supply chain data management provider – has warned that the UK is heading very rapidly down the wrong direction with vaccine passports. The Government last week announced its intention to use the NHS app to...
News
DCGI approves anti-COVID drug developed by DRDO for emergency use
The Drugs Controller General of India has approved an anti-COVID oral drug, developed by DRDO, for emergency use as adjunct therapy in moderate to severe coronavirus patients, the defence ministry said.
It said clinical trials of the drug 2-deoxy-D-glucose (2-DG)...
News
Russia authorises use of single-dose Covid-19 vaccine Sputnik Light
Sputnik Light, which is based on the human adenoviral vector platform, is the first component, a recombinant human adenovirus serotype number 26 (rAd26), of the Sputnik V Covid-19 vaccine.
Sputnik V has received authorisation in several countries. According to the...
Drug Research
Novavax Covid-19 vaccine provides cross-protection against B.1.351 variant
The protein-based vaccine candidate NVX-CoV2373 is made from the genetic sequence of the first SARS-CoV-2 strain. It is adjuvanted with the company’s saponin-based Matrix-M to boost immune response and neutralising antibodies. The candidate proved to offer a high level...
Drug Research
3P Biopharmaceuticals and Buzzard Pharmaceuticals start a collaboration to develop a new treatment to combat solid tumours
3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organisation CDMO specialized in the process development and GMP manufacturing of biologics and Buzzard Pharmaceuticals, a Swedish pharmaceutical company developing and re-positioning drugs in oncology.
Buzzard and 3P began their collaboration at...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















